Copyright
©The Author(s) 2020.
World J Diabetes. Apr 15, 2020; 11(4): 137-149
Published online Apr 15, 2020. doi: 10.4239/wjd.v11.i4.137
Published online Apr 15, 2020. doi: 10.4239/wjd.v11.i4.137
Table 1 Definitions of the primary efficacy outcome in each of the included trials
| Trial | Definition of primary efficacy outcome |
| CHANCE 2013 | Stroke recurrence (ischemic or hemorrhagic). |
| CHARISM 2006 | The composite of myocardial infarction, stroke, or death from cardiovascular causes. |
| CREDO 2002 | The composite of death, myocardial infarction, and stroke. |
| CURE 2001 | The composite of myocardial infarction, stroke, or death from cardiovascular causes. |
| POINT 2018 | The composite of ischemic stroke, myocardial infarction, or death from ischemic vascular causes. |
| SPS3 2012 | Stroke recurrence (ischemic or hemorrhagic). |
- Citation: Liang LR, Ma Q, Feng L, Qiu Q, Zheng W, Xie WX. Long-term effect of clopidogrel in patients with and without diabetes: A systematic review and meta-analysis of randomized controlled trials. World J Diabetes 2020; 11(4): 137-149
- URL: https://www.wjgnet.com/1948-9358/full/v11/i4/137.htm
- DOI: https://dx.doi.org/10.4239/wjd.v11.i4.137